LIN-004

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameLIN-004
Drug Alias NameAuristatin-Lx-HyB3AF-Lx-HyB3LIN-004
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionMelanoma-specific antigens modulators
TargetsMelanoma-specific antigens
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLinXis BV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLinXis BVAPO-T
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A